ACUTE MYELOID-LEUKEMIA

There has been considerable progress in the understanding and treatmen t of childhood acute myeloid leukaemia over the past two decades. In p articular, cyto- and molecular genetics offer the potential for more s pecific diagnosis of what is basically a heterogeneous disease. To dat e treatment has been based on a steady increase in cytotoxic chemother apy with or without the addition of bone marrow transplantation. Rando mised therapeutic trials are difficult to perform in what is a rare di sease. The best way Forward is for paediatric trial groups worldwide t o collaborate in developing common, or parallel, therapeutic protocols .